Diagnostics for monitoring the development of the HIV reservoar

Purpose and goal:

The project aims to develop a diagnostic product to monitor the individual need for antiviral treatment against HIV. By using a new method, CAD-seq, we can detect HIV-infected cells that are capable of producing new virus, the so-called "reservoir". This product also has potential to be used for early detection of virus-induced cancer, such as HPV-induced cervical cancer.

Expected results and effects:

Our solution offers a new type of HIV monitoring that does not exist today. Advantages in healthcare are that we will provide a better analysis in a cheap and simple way, without modifying routines. Expected effects are to improve health and efficiency in healthcare by offering an innovative solution for monitoring and treating HIV.

By using the CAD-seq method, we can detect HIV-infected cells that are capable of producing new virus, which makes it possible to individualize the treatment based on individual needs and conditions. Approach and implementation:

The project involves four partners from different sectors: Karolinska Institutet (KI), Karolinska Universitetssjukhuset Huddinge (KUS), Karolinska Universitetslaboratoriet (KUL) and Noaks Ark (patient organization). The expected results at the end of the project are a validated diagnostic product, a regulatory strategy and a business plan to sustainably meet the global societal challenge that the HIV epidemic still poses.